Prior to Nixon’s War on Drugs in the 70s, tens of millions of dollars were being poured into psychedelic research for treating mental health issues such as schizophrenia—and in recent years, new life has been breathed into psychedelic research for therapeutic treatment that has led to a nascent and investable sector. Jeff Siegel, managing partner at JLS Fund, provides an overview of the psychedelics space and why now is a good time to invest in it. He also shares how the science around psychedelic research is progressing, his future outlook on the sector’s growth, and how psychedelic therapy can fundamentally transform the future of mental health care. Interviewed by Ash Bennington on August 5, 2021.